Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns

Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Resende, Heloísa M., Ladislau, Leandro, Cardoso, Ana Carolina F., Brandão, Juliana Dinéia P., Assis, Biazi R., Cardoso, Paola, Marassi, Pedro Henrique A., Castilho, Vivienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457873/
https://www.ncbi.nlm.nih.gov/pubmed/34415791
http://dx.doi.org/10.1200/GO.20.00649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457873/
https://www.ncbi.nlm.nih.gov/pubmed/34415791
http://dx.doi.org/10.1200/GO.20.00649

Ejemplares similares